Modern aspects of safety of 5a-reductase inhibitors
- Authors: Vinarov A.Z1, Voskanyan G.A1, Rokhlikov I.M1, Spivak L.G1
-
Affiliations:
- Issue: No 6 (2012)
- Pages: 106-109
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279652
- ID: 279652
Cite item
Open Access
Access granted
Abstract
Full Text
About the authors
A. Z Vinarov
G. A Voskanyan
I. M Rokhlikov
L. G Spivak
Email: leonid.spivak@gmail.com
References
- Thompson I.M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003;349:215-224.
- Andriole G.L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 2010;362:1192-1202.
- Food and Drug Administration. Briefing information and slides presented at the December 1, 2010, meeting of the Oncologic Drugs Advisory Committee.
- Dutasteride label updates: GSK Advisory board meeting report. 21 March 2012. NH Eurobuilding Hotel, Madrid, Spain.
- Roehrborn C.G. et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. European Urology; Published online ahead of print 19 September 2009.
Supplementary files
